ERBB2 and cancer: In the past three decades, abnormal expression and increased activation of members of the HER family have been reported in a wide range of human malignancies and of these EGFR and HER-2 are important therapeutic targets for treatment with several monoclonal antibody based products and different forms of the HER inhibitors in a wide range of cancers.